exRNAdisease

General Information

Database ID:

exR0083466

RNA Name:

TPM4

RNA Type:

mRNA

Chromosome:

chr19

Starnd:

Coordinate:

Start Site(bp):

16067021

End Site(bp):

16103002

External Links:

Disease Information

Disease Name:	Fragile X Syndrome
Disease Category:	Congenital, Hereditary, and Neonatal Diseases and Abnormalities
MeSH ID:	D005600
Type:	Diseases Category/Congenital, Hereditary, and Neonatal Diseases and Abnormalities
Alias:	Fragile X Syndromes//Syndrome, Fragile X//Syndromes, Fragile X//Marker X Syndrome//Marker X Syndromes//Syndrome, Marker X//Syndromes, Marker X//Mental Retardation, X-Linked, Associated With Marxq28//X-Linked Mental Retardation and Macroorchidism//X Linked Mental Retardation and Macroorchidism//Fragile X Mental Retardation Syndrome//Martin-Bell Syndrome//Martin Bell Syndrome//Syndrome, Martin-Bell//Fra(X) Syndrome//FRAXE Syndrome//FRAXE Syndromes//Syndrome, FRAXE//Syndromes, FRAXE//Mental Retardation, X-Linked, Associated With Fragile Site Fraxe//Fragile X-F Mental Retardation Syndrome//Mar (X) Syndrome//FRAXA Syndrome//FRAXA Syndromes//Syndrome, FRAXA//Syndromes, FRAXA

Expression Detail

GEO ID:	GSE83556
Description:	Global transcriptome dysregulation in second trimester fetuses with FMR1 expansions
Experimental Design:	Disease vs Control
Case Disease Type:	Fragile X Syndrome
Case Disease SubType:	NA
Case Sample:	Fragile X Syndrome
Control Sample:	Normal
Number of Case:	22
Number of Control:	18
Number of Samples:	40

Regulatory Relationship

mRNA targets:

Gene Symbol	Chromosome	Start Site(bp)	End Site(bp)	Strand
AAMDC	chr11	77821109	77918432	+
AAMP	chr2	218264123	218270257	-
AARSD1	chr17	42950526	42964498	-
ABL1	chr9	130713016	130887675	+
AC004922.1	chr7	99325879	99394653	+
AC007192.1	chr19	18153158	18178117	+
AC048338.1	chr12	122207779	122266423	-
AC138696.1	chr8	143247110	143276403	+
AC245033.1	chr15	82536788	82573194	-
ACLY	chr17	41866917	41930542	-
ACTB	chr7	5527148	5563784	-
ACTG1	chr17	81509971	81523847	-
ADCY5	chr3	123282296	123449758	-
ADCY6	chr12	48766194	48789037	-
ADIPOR2	chr12	1688574	1788674	+
ADPGK	chr15	72751369	72785846	-
ADRM1	chr20	62302093	62308862	+
AGAP3	chr7	151085831	151144436	+
AHCY	chr20	34280268	34311802	-
AKT2	chr19	40230317	40285536	-
AL136454.1	chr1	192716132	192716653	+
AL365205.1	chr6	41780349	41790141	+
ALDOA	chr16	30064164	30070457	+

miRNA targets:

miRNA Symbol	Chromosome	Start Site(bp)	End Site(bp)	Strand
hsa-miR-139-5p	chr11	72615102	72615124	-
hsa-miR-185-5p	chr22	20033153	20033174	+
hsa-miR-1270	chr19	20399320	20399342	-

circRNA targets:

lncRNA targets:

lncRNA Symbol	Chromosome	Start Site(bp)	End Site(bp)	Strand
AC008969.1	chr19	58002061	58011232	+
AC016876.2	chr17	7581964	7584086	-
AC026362.1	chr12	122975320	122982907	+
AC026464.2	chr16	69463844	69466264	+
AC079807.1	chr2	47905678	47907810	+
AC099343.3	chr4	184471924	184472609	-
AC132217.1	chr11	2129121	2129964	-

Display:

Experiment Detail

GEO ID:	GSE83556
Sample Source:	Amniotic Fluid
Source Fraction:	Supernatant
Platform:	GPL570
Method:	Microarray
Num of detected RNA Type:	1
Num of detected RNAs of this Type:	17063
Sample treatment protocol:	RNA was extracted from 5-15 mL amniotic fluid supernatant (centrifugation at 350g, 4C, 10, min).
RNA Extract protocol:	All samples were processed using the Qiagen Circulating Nucleic Acid kit with an on-column DNase digestion step to remove genomic DNA. The RNA was then purified and concentrated with the RNeasy MinElute Clean up kit and eluted in RNasefree water.
RNA library preparation protocol:	RNA was converted to cDNA and amplified using the Ovation Pico WTA kit V2 and then purified with the QIAquick PCR Purification kit. Samples were labeled using the Encore Biotin Module (NuGEN, San Carlos, CA)Samples were labeled using the Encore Biotin Module (NuGEN, San Carlos, CA).

Reference